Author

F. Warnberg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:mouse· 1

Frequent Co-Authors

B. Nystedt· 1 shared E. Nimeus· 1 shared G. Martinez-Nieto· 1 shared G. Pekar· 1 shared G. Rask· 1 shared H. J. Ruotsalainen· 1 shared H. Peltoketo· 1 shared I. Fredriksson· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

B. Nystedt

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Evolution of ipsilateral breast cancer decoded by proteogenomics

T. De Marchi, P. T. Pyl, M. Sjostrom, S. E. Reinsbach, S. DiLorenzo, B. Nystedt, L. Tran, G. Pekar, F. Warnberg, I. Fredriksson, P. Malmstrom, M. Ferno, L. Malmstrom, J. Malmstrom, E. Nimeus

This study uses proteogenomics to analyze primary breast cancers and their ipsilateral recurrences, identifying molecular changes linked to recurrence and genomic instability.

bioRxiv · Jul 13, 2022 · PreprintCancer Biology

Collagen XVIII promotes breast cancer through EGFR/ErbB signaling and its ablation improves the efficacy of ErbB-targeting inhibitors

R. Devarajan, H. Peltoketo, V. Izzi, H. J. Ruotsalainen, S. Kauppila, M.-R. Vaisanen, G. Rask, G. Martinez-Nieto, S.-M. Karppinen, T. Vaisanen, I. Kaur, J. P. Koivunen, T. Sasaki, R. Winqvist, F. Warnberg, , R. Heljasvaara

This study shows that collagen XVIII promotes breast cancer via EGFR/ErbB signaling and sustains cancer stem cells, and its inhibition enhances the effectiveness of ErbB-targeting therapies.

bioRxiv · Jan 10, 2022 · PreprintCancer Biology